1
|
Hamad J, Shaw B, Kohen L, Linos K, Friedman BJ. Sclerosing melanocytic tumors with MAP2K1 in-frame deletions and copy number gains in 15q: A distinctive pathway of nevogenesis. J Cutan Pathol 2024; 51:284-287. [PMID: 38149342 PMCID: PMC10922240 DOI: 10.1111/cup.14586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 11/22/2023] [Accepted: 12/11/2023] [Indexed: 12/28/2023]
Affiliation(s)
- J Hamad
- Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA
| | - B Shaw
- Department of Pathology and Laboratory Medicine, Henry Ford Health, Detroit, Michigan, USA
| | - L Kohen
- Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA
| | - K Linos
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - B J Friedman
- Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA
| |
Collapse
|
2
|
Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Ann Oncol 2023; 34:1152-1164. [PMID: 37797734 DOI: 10.1016/j.annonc.2023.09.3110] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 09/12/2023] [Accepted: 09/25/2023] [Indexed: 10/07/2023] Open
Abstract
BACKGROUND Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy and safety of PARP inhibitor rechallenge. PATIENTS AND METHODS This randomized, double-blind, multicenter trial (NCT03106987) enrolled patients with platinum-sensitive relapsed ovarian cancer who had received one prior PARP inhibitor therapy for ≥18 and ≥12 months in the BRCA-mutated and non-BRCA-mutated cohorts, respectively, following first-line chemotherapy or for ≥12 and ≥6 months, respectively, following a second or subsequent line of chemotherapy. Patients were in response following their last platinum-based chemotherapy regimen and were randomized 2 : 1 to maintenance olaparib tablets 300 mg twice daily or placebo. Investigator-assessed progression-free survival (PFS) was the primary endpoint. RESULTS Seventy four patients in the BRCA-mutated cohort were randomized to olaparib and 38 to placebo, and 72 patients in the non-BRCA-mutated cohort were randomized to olaparib and 36 to placebo; >85% of patients in both cohorts had received ≥3 prior lines of chemotherapy. In the BRCA-mutated cohort, the median PFS was 4.3 months with olaparib versus 2.8 months with placebo [hazard ratio (HR) 0.57; 95% confidence interval (CI) 0.37-0.87; P = 0.022]; 1-year PFS rates were 19% versus 0% (Kaplan-Meier estimates). In the non-BRCA-mutated cohort, median PFS was 5.3 months for olaparib versus 2.8 months for placebo (HR 0.43; 95% CI 0.26-0.71; P = 0.0023); 1-year PFS rates were 14% versus 0% (Kaplan-Meier estimates). No new safety signals were identified with olaparib rechallenge. CONCLUSIONS In ovarian cancer patients previously treated with one prior PARP inhibitor and at least two lines of platinum-based chemotherapy, maintenance olaparib rechallenge provided a statistically significant, albeit modest, PFS improvement over placebo in both the BRCA-mutated and non-BRCA-mutated cohorts, with a proportion of patients in the maintenance olaparib rechallenge arm of both cohorts remaining progression free at 1 year.
Collapse
Affiliation(s)
- E Pujade-Lauraine
- Association de Recherche Cancers Gynécologiques (ARCAGY)-Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Paris; GINECO, Paris.
| | - F Selle
- GINECO, Paris; Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France
| | - G Scambia
- Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica, Rome; Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Milan, Italy
| | - B Asselain
- Association de Recherche Cancers Gynécologiques (ARCAGY)-Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Paris; GINECO, Paris
| | - F Marmé
- University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Studiengruppe, Essen, Germany
| | - K Lindemann
- Department of Gynaecological Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo; Nordic Society of Gynecologic Oncology (NSGO), Oslo, Norway
| | - N Colombo
- University of Milan-Bicocca and IEO European Institute of Oncology IRCCS, Milan; Mario Negri Gynecologic Oncology Group (MANGO), Italy
| | - R Mądry
- Uniwersytet Medyczny im.K.Marcinkowskiego w Poznaniu, Poznań; Polish Gynecologic Oncology Group (PGOG), Poznan, Poland
| | - R Glasspool
- Beatson West of Scotland Cancer Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow; National Cancer Research Institute (NCRI), London; Scottish Gynaecological Cancer Trials Group (SGCTG), Edinburgh, UK
| | - I Vergote
- University Hospitals Leuven, Leuven Cancer Institute, Leuven; Belgian and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium
| | - J Korach
- Sheba Medical Center, Tel Aviv University, Tel Hashomer, Ramat Gan; Israeli Society of Gynecologic Oncology (ISGO), Tel Aviv, Israel
| | - S Lheureux
- Princess Margaret Hospital, Department of Medical Oncology, Toronto; Princess Margaret Consortium, Toronto, Canada
| | - C Dubot
- GINECO, Paris; Oncologie Médicale, Institut Curie Saint Cloud, Paris, France
| | - A Oaknin
- Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona; Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain
| | - C Zamagni
- Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Milan, Italy; IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy
| | - F Heitz
- Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen; Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin; Berlin Institute of Health, Berlin; AGO Studiengruppe, Wiesbaden, Germany
| | - L Gladieff
- GINECO, Paris; Institut Claudius Regaud IUCT-Oncopole, Toulouse, France
| | - M J Rubio-Pérez
- Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain; Reina Sofia University Hospital, Cordoba, Spain
| | - P Scollo
- Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Milan, Italy; Kore University Enna, Enna; Dipartimento di Ginecologia e Ostetricia, Ospedale Cannizzaro, Catania, Italy
| | | | - B Shaw
- AstraZeneca, Cambridge, UK
| | - I Ray-Coquard
- GINECO, Paris; Medical Oncology Department, Centre Léon Bérard and University Claude Bernard Lyon, Lyon, France
| | - A Redondo
- Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain; La Paz University Hospital-IdiPAZ, Madrid, Spain
| |
Collapse
|
3
|
Gaitonde P, Liljas B, Shaw B, Miranda P. PB1877: ADJUSTING SURVIVAL DATA FOR TREATMENT CROSSOVER IN THE ELEVATE-TN TRIAL BY USING A HISTORICAL COHORT OF PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY IN FRONT-LINE CHRONIC LYMPHOCYTIC LEUKEMIA. Hemasphere 2022. [PMCID: PMC9431704 DOI: 10.1097/01.hs9.0000850360.32912.a6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Abba A, Accorsi C, Agnes P, Alessi E, Amaudruz P, Annovi A, Desages FA, Back S, Badia C, Bagger J, Basile V, Batignani G, Bayo A, Bell B, Beschi M, Biagini D, Bianchi G, Bicelli S, Bishop D, Boccali T, Bombarda A, Bonfanti S, Bonivento WM, Bouchard M, Breviario M, Brice S, Brown R, Calvo-Mozota JM, Camozzi L, Camozzi M, Capra A, Caravati M, Carlini M, Ceccanti A, Celano B, Cela Ruiz JM, Charette C, Cogliati G, Constable M, Crippa C, Croci G, Cudmore S, Dahl CE, Dal Molin A, Daley M, Di Guardo C, D'Avenio G, Davignon O, Del Tutto M, De Ruiter J, Devoto A, Diaz Gomez Maqueo P, Di Francesco F, Dossi M, Druszkiewicz E, Duma C, Elliott E, Farina D, Fernandes C, Ferroni F, Finocchiaro G, Fiorillo G, Ford R, Foti G, Fournier RD, Franco D, Fricbergs C, Gabriele F, Galbiati C, Garcia Abia P, Gargantini A, Giacomelli L, Giacomini F, Giacomini F, Giarratana LS, Gillespie S, Giorgi D, Girma T, Gobui R, Goeldi D, Golf F, Gorel P, Gorini G, Gramellini E, Grosso G, Guescini F, Guetre E, Hackman G, Hadden T, Hawkins W, Hayashi K, Heavey A, Hersak G, Hessey N, Hockin G, Hudson K, Ianni A, Ienzi C, Ippolito V, James CC, Jillings C, Kendziora C, Khan S, Kim E, King M, King S, Kittmer A, Kochanek I, Kowalkowski J, Krücken R, Kushoro M, Kuula S, Laclaustra M, Leblond G, Lee L, Lennarz A, Leyton M, Li X, Liimatainen P, Lim C, Lindner T, Lomonaco T, Lu P, Lubna R, Lukhanin GA, Luzón G, MacDonald M, Magni G, Maharaj R, Manni S, Mapelli C, Margetak P, Martin L, Martin S, Martínez M, Massacret N, McClurg P, McDonald AB, Meazzi E, Migalla R, Mohayai T, Tosatti LM, Monzani G, Moretti C, Morrison B, Mountaniol M, Muraro A, Napoli P, Nati F, Natzke CR, Noble AJ, Norrick A, Olchanski K, Ortiz de Solorzano A, Padula F, Pallavicini M, Palumbo I, Panontin E, Papini N, Parmeggiano L, Parmeggiano S, Patel K, Patel A, Paterno M, Pellegrino C, Pelliccione P, Pesudo V, Pocar A, Pope A, Pordes S, Prelz F, Putignano O, Raaf JL, Ratti C, Razeti M, Razeto A, Reed D, Refsgaard J, Reilly T, Renshaw A, Retriere F, Riccobene E, Rigamonti D, Rizzi A, Rode J, Romualdez J, Russel L, Sablone D, Sala S, Salomoni D, Salvo P, Sandoval A, Sansoucy E, Santorelli R, Savarese C, Scapparone E, Schaubel T, Scorza S, Settimo M, Shaw B, Shawyer S, Sher A, Shi A, Skensved P, Slutsky A, Smith B, Smith NJT, Stenzler A, Straubel C, Stringari P, Suchenek M, Sur B, Tacchino S, Takeuchi L, Tardocchi M, Tartaglia R, Thomas E, Trask D, Tseng J, Tseng L, VanPagee L, Vedia V, Velghe B, Viel S, Visioli A, Viviani L, Vonica D, Wada M, Walter D, Wang H, Wang MHLS, Westerdale S, Wood D, Yates D, Yue S, Zambrano V. The novel Mechanical Ventilator Milano for the COVID-19 pandemic. Phys Fluids (1994) 2021; 33:037122. [PMID: 33897243 PMCID: PMC8060010 DOI: 10.1063/5.0044445] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/16/2021] [Accepted: 02/14/2021] [Indexed: 06/12/2023]
Abstract
This paper presents the Mechanical Ventilator Milano (MVM), a novel intensive therapy mechanical ventilator designed for rapid, large-scale, low-cost production for the COVID-19 pandemic. Free of moving mechanical parts and requiring only a source of compressed oxygen and medical air to operate, the MVM is designed to support the long-term invasive ventilation often required for COVID-19 patients and operates in pressure-regulated ventilation modes, which minimize the risk of furthering lung trauma. The MVM was extensively tested against ISO standards in the laboratory using a breathing simulator, with good agreement between input and measured breathing parameters and performing correctly in response to fault conditions and stability tests. The MVM has obtained Emergency Use Authorization by U.S. Food and Drug Administration (FDA) for use in healthcare settings during the COVID-19 pandemic and Health Canada Medical Device Authorization for Importation or Sale, under Interim Order for Use in Relation to COVID-19. Following these certifications, mass production is ongoing and distribution is under way in several countries. The MVM was designed, tested, prepared for certification, and mass produced in the space of a few months by a unique collaboration of respiratory healthcare professionals and experimental physicists, working with industrial partners, and is an excellent ventilator candidate for this pandemic anywhere in the world.
Collapse
Affiliation(s)
- A. Abba
- Nuclear Instruments S.R.L., Como 22045, Italy
| | - C. Accorsi
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | - P. Agnes
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - E. Alessi
- Istituto per la Scienza e Tecnologia dei Plasmi, ISTP-CNR, Milano 20125, Italy
| | - P. Amaudruz
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A. Annovi
- INFN Sezione di Pisa, Pisa 56127, Italy
| | - F. Ardellier Desages
- APC, Université de Paris, CNRS, Astroparticule et Cosmologie, F-75013 Paris, France
| | - S. Back
- SNOLAB, Lively, Ontario P3Y 1N2, Canada
| | - C. Badia
- Gran Sasso Science Institute, L'Aquila 67100, Italy
| | - J. Bagger
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - V. Basile
- Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato, CNR STIIMA, Milano 20133, Italy
| | | | - A. Bayo
- LSC, Laboratorio Subterráneo de Canfranc, Canfranc-Estación 22880, Spain
| | - B. Bell
- JMP Solutions, London, Ontario N6N 1E2, Canada
| | | | - D. Biagini
- Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Pisa 56124, Italy
| | - G. Bianchi
- Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato, CNR STIIMA, Milano 20133, Italy
| | - S. Bicelli
- Camozzi Group S.p.A., Brescia BS 25126, Italy
| | - D. Bishop
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | | | - A. Bombarda
- Dipartimento di Ingegneria Gestionale, dell'Informazione e della Produzione, Università di Bergamo, Bergamo, 24129, Italy
| | - S. Bonfanti
- Dipartimento di Ingegneria Gestionale, dell'Informazione e della Produzione, Università di Bergamo, Bergamo, 24129, Italy
| | | | - M. Bouchard
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - M. Breviario
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | - S. Brice
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R. Brown
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - J. M. Calvo-Mozota
- LSC, Laboratorio Subterráneo de Canfranc, Canfranc-Estación 22880, Spain
| | - L. Camozzi
- Camozzi Group S.p.A., Brescia BS 25126, Italy
| | - M. Camozzi
- Camozzi Group S.p.A., Brescia BS 25126, Italy
| | - A. Capra
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - M. Caravati
- INFN Sezione di Cagliari, Cagliari 09042, Italy
| | - M. Carlini
- Gran Sasso Science Institute, L'Aquila 67100, Italy
| | | | - B. Celano
- INFN Sezione di Napoli, Napoli 80126, Italy
| | - J. M. Cela Ruiz
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain
| | - C. Charette
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - G. Cogliati
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | - M. Constable
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - C. Crippa
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | - G. Croci
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano 20126, Italy
| | - S. Cudmore
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | | | - A. Dal Molin
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano 20126, Italy
| | - M. Daley
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - C. Di Guardo
- Dipartimento di Scienze Economiche ed Aziendali, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | - G. D'Avenio
- National Center for Innovative Technologies in Public Health, ISS (Italy National Institute of Health), Roma 00161, Italy
| | - O. Davignon
- Laboratoire Leprince Ringuet, École Polytechnique, Palaiseau, Cedex 91128, France
| | - M. Del Tutto
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J. De Ruiter
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - A. Devoto
- Dipartimento di Fisica, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | | | - F. Di Francesco
- Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Pisa 56124, Italy
| | - M. Dossi
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | - E. Druszkiewicz
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - C. Duma
- INFN-CNAF, Bologna 40127, Italy
| | - E. Elliott
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - D. Farina
- Istituto per la Scienza e Tecnologia dei Plasmi, ISTP-CNR, Milano 20125, Italy
| | | | | | | | | | - R. Ford
- SNOLAB, Lively, Ontario P3Y 1N2, Canada
| | | | | | - D. Franco
- APC, Université de Paris, CNRS, Astroparticule et Cosmologie, F-75013 Paris, France
| | | | - F. Gabriele
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | | | - P. Garcia Abia
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain
| | - A. Gargantini
- Dipartimento di Ingegneria Gestionale, dell'Informazione e della Produzione, Università di Bergamo, Bergamo, 24129, Italy
| | - L. Giacomelli
- Istituto per la Scienza e Tecnologia dei Plasmi, ISTP-CNR, Milano 20125, Italy
| | | | | | | | - S. Gillespie
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - D. Giorgi
- Camozzi Group S.p.A., Brescia BS 25126, Italy
| | - T. Girma
- VEXOS, Markham, Ontario L3R 9X6, Canada
| | - R. Gobui
- VEXOS, Markham, Ontario L3R 9X6, Canada
| | | | - F. Golf
- Department of Physics and Astronomy, University of Nebraska-Lincoln, Lincoln, Nebraska 68508, USA
| | - P. Gorel
- SNOLAB, Lively, Ontario P3Y 1N2, Canada
| | - G. Gorini
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano 20126, Italy
| | - E. Gramellini
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G. Grosso
- Istituto per la Scienza e Tecnologia dei Plasmi, ISTP-CNR, Milano 20125, Italy
| | - F. Guescini
- Max-Planck-Institut für Physik (Werner-Heisenberg-Institut), 80805 München, Germany
| | - E. Guetre
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - G. Hackman
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - T. Hadden
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | | | - K. Hayashi
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A. Heavey
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G. Hersak
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - N. Hessey
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - G. Hockin
- JMP Solutions, London, Ontario N6N 1E2, Canada
| | - K. Hudson
- VEXOS, Markham, Ontario L3R 9X6, Canada
| | - A. Ianni
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - C. Ienzi
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | | | - C. C. James
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | | | - C. Kendziora
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S. Khan
- VEXOS, Markham, Ontario L3R 9X6, Canada
| | - E. Kim
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - M. King
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - S. King
- JMP Solutions, London, Ontario N6N 1E2, Canada
| | - A. Kittmer
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - I. Kochanek
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - J. Kowalkowski
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | | | - M. Kushoro
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano 20126, Italy
| | - S. Kuula
- SNOLAB, Lively, Ontario P3Y 1N2, Canada
| | | | - G. Leblond
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - L. Lee
- Department of APT, Faculty of Medicine, University of British Columbia, Vancouver V5Z 1M9, Canada
| | - A. Lennarz
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - M. Leyton
- INFN Sezione di Napoli, Napoli 80126, Italy
| | - X. Li
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | | | - C. Lim
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - T. Lindner
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - T. Lomonaco
- Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Pisa 56124, Italy
| | - P. Lu
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - R. Lubna
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - G. A. Lukhanin
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G. Luzón
- CAPA (Centro de Astropartículas y Física de Altas Energías), Universidad de Zaragoza, Zaragoza 50009, Spain
| | - M. MacDonald
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - G. Magni
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | - R. Maharaj
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - S. Manni
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - C. Mapelli
- Dipartimento di Meccanica, Politecnico di Milano, Milano 20156, Italy
| | - P. Margetak
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - L. Martin
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - S. Martin
- VEXOS, Markham, Ontario L3R 9X6, Canada
| | | | - N. Massacret
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - P. McClurg
- Department of Respiratory and Anaesthesia Technology, Vanier College, Montréal, Quebec H4L 3X9, Canada
| | | | - E. Meazzi
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | | | - T. Mohayai
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L. M. Tosatti
- Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato, CNR STIIMA, Milano 20133, Italy
| | - G. Monzani
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | - C. Moretti
- Dipartimento di Pediatria, Sapienza Università di Roma, Roma 00185, Italy
| | | | | | - A. Muraro
- Istituto per la Scienza e Tecnologia dei Plasmi, ISTP-CNR, Milano 20125, Italy
| | - P. Napoli
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | - F. Nati
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano 20126, Italy
| | - C. R. Natzke
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | | | - A. Norrick
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K. Olchanski
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A. Ortiz de Solorzano
- CAPA (Centro de Astropartículas y Física de Altas Energías), Universidad de Zaragoza, Zaragoza 50009, Spain
| | - F. Padula
- School of Civil and Mechanical Engineering, Curtin University, Perth (Washington), Australia
| | | | - I. Palumbo
- Azienda Ospedaliera San Gerardo, Monza 20900, Italy
| | - E. Panontin
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano 20126, Italy
| | - N. Papini
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | | | | | - K. Patel
- VEXOS, Markham, Ontario L3R 9X6, Canada
| | - A. Patel
- VEXOS, Markham, Ontario L3R 9X6, Canada
| | - M. Paterno
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | | | | | | | - A. Pocar
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - A. Pope
- JMP Solutions, London, Ontario N6N 1E2, Canada
| | - S. Pordes
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - F. Prelz
- INFN Sezione di Milano, Milano 20133, Italy
| | - O. Putignano
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano 20126, Italy
| | - J. L. Raaf
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C. Ratti
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | - M. Razeti
- INFN Sezione di Cagliari, Cagliari 09042, Italy
| | - A. Razeto
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - D. Reed
- Equilibar L.L.C., Fletcher, North Carolina 28732, USA
| | - J. Refsgaard
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - T. Reilly
- VEXOS, Markham, Ontario L3R 9X6, Canada
| | - A. Renshaw
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - F. Retriere
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - E. Riccobene
- Dipartimento di Informatica, Universitá degli Studi di Milano, Milano 20122, Italy
| | - D. Rigamonti
- Istituto per la Scienza e Tecnologia dei Plasmi, ISTP-CNR, Milano 20125, Italy
| | | | | | - J. Romualdez
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - L. Russel
- JMP Solutions, London, Ontario N6N 1E2, Canada
| | - D. Sablone
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - S. Sala
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | | | - P. Salvo
- Istituto di Fisiologia Clinica del CNR, IFC-CNR, Pisa 56124, Italy
| | | | - E. Sansoucy
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - R. Santorelli
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain
| | - C. Savarese
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | | | - T. Schaubel
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - S. Scorza
- SNOLAB, Lively, Ontario P3Y 1N2, Canada
| | - M. Settimo
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes 44300, France
| | - B. Shaw
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - S. Shawyer
- JMP Solutions, London, Ontario N6N 1E2, Canada
| | - A. Sher
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A. Shi
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | | | - A. Slutsky
- St. Michael's Hospital, Unity Health Toronto, Ontario M5B 1W8, Canada
| | - B. Smith
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | | | - A. Stenzler
- 12th Man Technologies, Garden Grove, California 92841, USA
| | - C. Straubel
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - P. Stringari
- MINES ParisTech, PSL University, CTP-Centre of Thermodynamics of Processes, 77300 Fontainebleau, France
| | - M. Suchenek
- AstroCeNT, Nicolaus Copernicus Astronomical Center, Polish Academy of Sciences, Warsaw 00-614, Poland
| | - B. Sur
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | | | - L. Takeuchi
- Department of Medicine, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - M. Tardocchi
- Istituto per la Scienza e Tecnologia dei Plasmi, ISTP-CNR, Milano 20125, Italy
| | - R. Tartaglia
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - E. Thomas
- Arthur B. McDonald Canadian Astroparticle Research Institute, Kingston, Ontario K7L 3N6, Canada
| | - D. Trask
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - J. Tseng
- Department of Physics, University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - L. Tseng
- VEXOS, Markham, Ontario L3R 9X6, Canada
| | - L. VanPagee
- JMP Solutions, London, Ontario N6N 1E2, Canada
| | - V. Vedia
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - B. Velghe
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | | | - A. Visioli
- Dipartimento di Ingegneria Meccanica e Industriale, Università degli Studi di Brescia, Brescia 25123, Italy
| | - L. Viviani
- Elemaster Group S.p.A., Lomagna (LC) 23871, Italy
| | - D. Vonica
- VEXOS, Markham, Ontario L3R 9X6, Canada
| | - M. Wada
- AstroCeNT, Nicolaus Copernicus Astronomical Center, Polish Academy of Sciences, Warsaw 00-614, Poland
| | - D. Walter
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - H. Wang
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
| | - M. H. L. S. Wang
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | | | - D. Wood
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - D. Yates
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - S. Yue
- Canadian Nuclear Laboratories, Chalk River K0J 1J0, Canada
| | - V. Zambrano
- CAPA (Centro de Astropartículas y Física de Altas Energías), Universidad de Zaragoza, Zaragoza 50009, Spain
| |
Collapse
|
5
|
Elisofon SA, Magee JC, Ng VL, Horslen SP, Fioravanti V, Economides J, Erinjeri J, Anand R, Mazariegos GV, Martin A, Mannino D, Flynn L, Mohammad S, Alonso E, Superina R, Brandt K, Riordan M, Lokar J, Ito J, Elisofon S, Zapata L, Jain A, Foristal E, Gupta N, Whitlow C, Naik K, Espinosa H, Miethke A, Hawkins A, Hardy J, Engels E, Schreibeis A, Ovchinsky N, Kogan‐Liberman D, Cunningham R, Malik P, Sundaram S, Feldman A, Garcia B, Yanni G, Kohli R, Emamaullee J, Secules C, Magee J, Lopez J, Bilhartz J, Hollenbeck J, Shaw B, Bartow C, Forest S, Rand E, Byrne A, Linguiti I, Wann L, Seidman C, Mazariegos G, Soltys K, Squires J, Kepler A, Vitola B, Telega G, Lerret S, Desai D, Moghe J, Cutright L, Daniel J, Andrews W, Fioravanti V, Slowik V, Cisneros R, Faseler M, Hufferd M, Kelly B, Sudan D, Mavis A, Moats L, Swan‐Nesbit S, Yazigi N, Buranych A, Hobby A, Rao G, Maccaby B, Gopalareddy V, Boulware M, Ibrahim S, El Youssef M, Furuya K, Schatz A, Weckwerth J, Lovejoy C, Kasi N, Nadig S, Law M, Arnon R, Chu J, Bucuvalas J, Czurda M, Secheli B, Almy C, Haydel B, Lobritto S, Emand J, Biney‐Amissah E, Gamino D, Gomez A, Himes R, Seal J, Stewart S, Bergeron J, Truxillo A, Lebel S, Davidson H, Book L, Ramstack D, Riley A, Jennings C, Horslen S, Hsu E, Wallace K, Turmelle Y, Nadler M, Postma S, Miloh T, Economides J, Timmons K, Ng V, Subramonian A, Dharmaraj B, McDiarmid S, Feist S, Rhee S, Perito E, Gallagher L, Smith K, Ebel N, Zerofsky M, Nogueira J, Greer R, Gilmour S, Robert C, Cars C, Azzam R, Boone P, Garbarino N, Lalonde M, Kerkar N, Dokus K, Helbig K, Grizzanti M, Tomiyama K, Cocking J, Alexopoulos S, Bhave C, Schillo R, Bailey A, Dulek D, Ramsey L, Ekong U, Valentino P, Hettiarachchi D, Tomlin R. Society of pediatric liver transplantation: Current registry status 2011-2018. Pediatr Transplant 2020; 24:e13605. [PMID: 31680409 DOI: 10.1111/petr.13605] [Citation(s) in RCA: 62] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 08/08/2019] [Accepted: 09/27/2019] [Indexed: 11/29/2022]
Abstract
BACKGROUND SPLIT was founded in 1995 in order to collect comprehensive prospective data on pediatric liver transplantation, including waiting list data, transplant, and early and late outcomes. Since 2011, data collection of the current registry has been refined to focus on prospective data and outcomes only after transplant to serve as a foundation for the future development of targeted clinical studies. OBJECTIVE To report the outcomes of the SPLIT registry from 2011 to 2018. METHODS This is a multicenter, cross-sectional analysis characterizing patients transplanted and enrolled in the SPLIT registry between 2011 and 2018. All patients, <18 years of age, received a first liver-only, a combined liver-kidney, or a combined liver-pancreas transplant during this study period. RESULTS A total of 1911 recipients from 39 participating centers in North America were registered. Indications included biliary atresia (38.5%), metabolic disease (19.1%), tumors (11.7%), and fulminant liver failure (11.5%). Greater than 50% of recipients were transplanted as either Status 1A/1B or with a MELD/PELD exception score. Incompatible transplants were performed in 4.1%. Kaplan-Meier estimates of 1-year patient and graft survival were 97.3% and 96.6%. First 30 days of surgical complications included reoperation (31.7%), hepatic artery thrombosis (6.3%), and portal vein thrombosis (3.2%). In the first 90 days, biliary tract complications were reported in 13.6%. Acute cellular rejection during first year was 34.7%. At 1 and 2 years of follow-up, 39.2% and 50.6% had normal liver tests on monotherapy (tacrolimus or sirolimus). Further surgical, survival, allograft function, and complications are detailed.
Collapse
Affiliation(s)
- Scott A Elisofon
- Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, Massachusetts
| | - John C Magee
- Division of Surgery, University of Michigan Transplant Center, Ann Arbor, Michigan
| | - Vicky L Ng
- Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Transplant and Regenerative Medicine Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
| | - Simon P Horslen
- Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington
| | - Vicki Fioravanti
- Section of Hepatology and Liver Transplantation, Children's Mercy Hospital, Kansas City, Missouri
| | | | | | | | - George V Mazariegos
- Division of Pediatric Transplant Surgery, Hillman Center for Pediatric Transplantation, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Vasquez E, Udo T, Corsino L, Shaw B. RACIAL DIFFERENCES IN THE ASSOCIATION BETWEEN CHILDHOOD ADVERSITY AND OBESITY IN A SAMPLE OF OLDER ADULTS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - T Udo
- University at Albany (SUNY)
| | - L Corsino
- Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition
| | - B Shaw
- University at Albany (Suny)
| |
Collapse
|
7
|
Bourne K, Stiles L, Shaw B, Raj S. SOCIOECONOMIC AND FINANCIAL IMPACT OF POSTURAL TACHYCARDIA SYNDROME: DATA FROM A PATIENT CROSS-SECTIONAL SURVEY. Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.07.119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
8
|
Amaudruz PA, Baldwin M, Batygov M, Beltran B, Bina CE, Bishop D, Bonatt J, Boorman G, Boulay MG, Broerman B, Bromwich T, Bueno JF, Burghardt PM, Butcher A, Cai B, Chan S, Chen M, Chouinard R, Cleveland BT, Cranshaw D, Dering K, DiGioseffo J, Dittmeier S, Duncan FA, Dunford M, Erlandson A, Fatemighomi N, Florian S, Flower A, Ford RJ, Gagnon R, Giampa P, Golovko VV, Gorel P, Gornea R, Grace E, Graham K, Gulyev E, Hakobyan R, Hall A, Hallin AL, Hamstra M, Harvey PJ, Hearns C, Jillings CJ, Kamaev O, Kemp A, Kuźniak M, Langrock S, La Zia F, Lehnert B, Lidgard JJ, Lim C, Lindner T, Linn Y, Liu S, Majewski P, Mathew R, McDonald AB, McElroy T, McGinn T, McLaughlin JB, Mead S, Mehdiyev R, Mielnichuk C, Monroe J, Muir A, Nadeau P, Nantais C, Ng C, Noble AJ, O'Dwyer E, Ohlmann C, Olchanski K, Olsen KS, Ouellet C, Pasuthip P, Peeters SJM, Pollmann TR, Rand ET, Rau W, Rethmeier C, Retière F, Seeburn N, Shaw B, Singhrao K, Skensved P, Smith B, Smith NJT, Sonley T, Soukup J, Stainforth R, Stone C, Strickland V, Sur B, Tang J, Taylor J, Veloce L, Vázquez-Jáuregui E, Walding J, Ward M, Westerdale S, Woolsey E, Zielinski J. First Results from the DEAP-3600 Dark Matter Search with Argon at SNOLAB. Phys Rev Lett 2018; 121:071801. [PMID: 30169081 DOI: 10.1103/physrevlett.121.071801] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 05/17/2018] [Indexed: 06/08/2023]
Abstract
This Letter reports the first results of a direct dark matter search with the DEAP-3600 single-phase liquid argon (LAr) detector. The experiment was performed 2 km underground at SNOLAB (Sudbury, Canada) utilizing a large target mass, with the LAr target contained in a spherical acrylic vessel of 3600 kg capacity. The LAr is viewed by an array of PMTs, which would register scintillation light produced by rare nuclear recoil signals induced by dark matter particle scattering. An analysis of 4.44 live days (fiducial exposure of 9.87 ton day) of data taken during the initial filling phase demonstrates the best electronic recoil rejection using pulse-shape discrimination in argon, with leakage <1.2×10^{-7} (90% C.L.) between 15 and 31 keV_{ee}. No candidate signal events are observed, which results in the leading limit on weakly interacting massive particle (WIMP)-nucleon spin-independent cross section on argon, <1.2×10^{-44} cm^{2} for a 100 GeV/c^{2} WIMP mass (90% C.L.).
Collapse
Affiliation(s)
- P-A Amaudruz
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - M Baldwin
- Rutherford Appleton Laboratory, Harwell Oxford, Didcot OX11 0QX, United Kingdom
| | - M Batygov
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - B Beltran
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - C E Bina
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - D Bishop
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - J Bonatt
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - G Boorman
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - M G Boulay
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - B Broerman
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - T Bromwich
- University of Sussex, Sussex House, Brighton, East Sussex BN1 9RH, United Kingdom
| | - J F Bueno
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - P M Burghardt
- Department of Physics, Technische Universität München, 80333 Munich, Germany
| | - A Butcher
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - B Cai
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S Chan
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - M Chen
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - R Chouinard
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - B T Cleveland
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - D Cranshaw
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - K Dering
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - J DiGioseffo
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S Dittmeier
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - F A Duncan
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - M Dunford
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - A Erlandson
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
- Canadian Nuclear Laboratories Ltd, Chalk River, Ontario K0J 1J0, Canada
| | - N Fatemighomi
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - S Florian
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - A Flower
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - R J Ford
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - R Gagnon
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - P Giampa
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - V V Golovko
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Canadian Nuclear Laboratories Ltd, Chalk River, Ontario K0J 1J0, Canada
| | - P Gorel
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - R Gornea
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - E Grace
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - K Graham
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - E Gulyev
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - R Hakobyan
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - A Hall
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - A L Hallin
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - M Hamstra
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - P J Harvey
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Hearns
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C J Jillings
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - O Kamaev
- Canadian Nuclear Laboratories Ltd, Chalk River, Ontario K0J 1J0, Canada
| | - A Kemp
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - M Kuźniak
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - S Langrock
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - F La Zia
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - B Lehnert
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - J J Lidgard
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Lim
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - T Lindner
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - Y Linn
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - S Liu
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - P Majewski
- Rutherford Appleton Laboratory, Harwell Oxford, Didcot OX11 0QX, United Kingdom
| | - R Mathew
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - A B McDonald
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - T McElroy
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - T McGinn
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - J B McLaughlin
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S Mead
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - R Mehdiyev
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - C Mielnichuk
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - J Monroe
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - A Muir
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - P Nadeau
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - C Nantais
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Ng
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - A J Noble
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - E O'Dwyer
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Ohlmann
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - K Olchanski
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - K S Olsen
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - C Ouellet
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - P Pasuthip
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S J M Peeters
- University of Sussex, Sussex House, Brighton, East Sussex BN1 9RH, United Kingdom
| | - T R Pollmann
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Technische Universität München, 80333 Munich, Germany
| | - E T Rand
- Canadian Nuclear Laboratories Ltd, Chalk River, Ontario K0J 1J0, Canada
| | - W Rau
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Rethmeier
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - F Retière
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - N Seeburn
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - B Shaw
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - K Singhrao
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - P Skensved
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - B Smith
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - N J T Smith
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - T Sonley
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - J Soukup
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - R Stainforth
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - C Stone
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - V Strickland
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - B Sur
- Canadian Nuclear Laboratories Ltd, Chalk River, Ontario K0J 1J0, Canada
| | - J Tang
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - J Taylor
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - L Veloce
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - E Vázquez-Jáuregui
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
- Instituto de Física, Universidad Nacional Autónoma de México, A. P. 20-364, México D. F. 01000, Mexico
| | - J Walding
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - M Ward
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S Westerdale
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - E Woolsey
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - J Zielinski
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| |
Collapse
|
9
|
Rodrigues SA, Guey J, Plummer TCH, Pullen A, Shaw B, Kieser DC. Influence of rib impact on thoracic gunshot trauma. J ROY ARMY MED CORPS 2018; 164:405-409. [PMID: 30093376 DOI: 10.1136/jramc-2018-000984] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Revised: 07/24/2018] [Accepted: 07/24/2018] [Indexed: 11/03/2022]
Abstract
INTRODUCTION The influence of rib impact on thoracic gunshot trauma remains unclear, despite its high occurrence. This study therefore investigates the effect of rib impact on a bullet's terminal properties and injury severity. METHODS Two bullets were used: 5.56×45 mm (full charge and reduced charge) and 7.62×51 mm (full charge). For each bullet, three impact groups were tested: (1) plain 10% ballistic gelatin (control) conditioned at 4°C, (2) intercostal impact, and (3) rib impact, the latter two tested with samples of porcine thoracic walls embedded in gelatin. Analysis included penetration depth, trajectory change, yaw, fragmentation, velocity reduction, energy deposition and temporary and permanent cavity characteristics. RESULTS No significant differences were observed for most variables. Differences were found between rib (and intercostal) impact and the control groups, suggesting that the inclusion of thoracic walls produces an effect more significant than the anatomical impact site. Effects were ammunition specific. For the 7.62×51 mm round, rib impact caused an earlier onset of yaw and more superficial permanent gelatin damage compared with plain gelatin. This round also formed a larger temporary cavity on rib impact than intercostal impact. Rib (and intercostal impact) created a smaller temporary cavity than the control for the 5.56×45 mm round. For the reduced-charge 5.56×45 mm round, rib and intercostal impact produced greater velocity reduction compared with plain gelatin. CONCLUSIONS This study provides new insights into the role of rib impact in thoracic gunshot injuries, and indicates that the effects are ammunition dependent. Unlike the 5.56×45 mm rounds, rib impact with the 7.62×51 mm rounds increases the risk of severe wounding.
Collapse
Affiliation(s)
- Samantha Alda Rodrigues
- Ballistics and Personnel Protection, Defence Technology Agency, New Zealand Defence Force, Auckland, New Zealand
| | - J Guey
- Ballistics and Personnel Protection, Defence Technology Agency, New Zealand Defence Force, Auckland, New Zealand
| | - T C H Plummer
- Ballistics and Personnel Protection, Defence Technology Agency, New Zealand Defence Force, Auckland, New Zealand
| | - A Pullen
- Ballistics and Personnel Protection, Defence Technology Agency, New Zealand Defence Force, Auckland, New Zealand
| | - B Shaw
- Ballistics and Personnel Protection, Defence Technology Agency, New Zealand Defence Force, Auckland, New Zealand
| | - D C Kieser
- Department of Orthopaedics and Musculoskeletal Medicine, Christchurch School of Medicine, University of Otago, Dunedin, New Zealand
| |
Collapse
|
10
|
Belch JJF, Shaw B, O’Dowd A, Saniabadi A, Leiberman P, Sturrock RD, Forbes CD. Evening Primrose Oil (Efamol) in the Treatment of Raynaud’s Phenomenon: A Double Blind Study. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1657880] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryProstaglandin E1 (PGE1) and prostacyclin have been used in Raynaud’s phenomenon (RP) but are unstable and require intravenous administration. An alternative approach is to stimulate the body’s own PGE1 production via administration of the precursor essential fatty acid. We studied the effect of 12 capsules/day of evening primrose oil (EPO) on the manifestations of RP. 21 patients received a two week course of placebo, thereafter 11 received EPO for 8 weeks and 10 patients received placebo. As the weather worsened the placebo group experienced significantly more attacks than the EPO group. Visual analogue scales assessing the severity of attacks and coldness of hands improved in the EPO group. No changes were seen in either group in hand temperatures and cold challenge plethysmography. Blood tests showed some antiplatelet effects of the drug. In conclusion patients receiving EPO benefited symptomatically. This was not matched however by any change in objective assessment of blood flow, although changes in platelet behaviour and blood prostanoids were observed.
Collapse
Affiliation(s)
- J J F Belch
- The Centre for Rheumatic Diseases, Department of Medicine and Vascular Surgery, Royal Infirmary, Glasgow, UK
| | - B Shaw
- The Centre for Rheumatic Diseases, Department of Medicine and Vascular Surgery, Royal Infirmary, Glasgow, UK
| | - A O’Dowd
- The Centre for Rheumatic Diseases, Department of Medicine and Vascular Surgery, Royal Infirmary, Glasgow, UK
| | - A Saniabadi
- The Centre for Rheumatic Diseases, Department of Medicine and Vascular Surgery, Royal Infirmary, Glasgow, UK
| | - P Leiberman
- The Centre for Rheumatic Diseases, Department of Medicine and Vascular Surgery, Royal Infirmary, Glasgow, UK
| | - R D Sturrock
- The Centre for Rheumatic Diseases, Department of Medicine and Vascular Surgery, Royal Infirmary, Glasgow, UK
| | - C D Forbes
- The Centre for Rheumatic Diseases, Department of Medicine and Vascular Surgery, Royal Infirmary, Glasgow, UK
| |
Collapse
|
11
|
Saniabadi AR, Lowe GDO, Madhok R, Spowart K, Shaw B, Barbenel JC, Forbes CD. A Critical Investigation into the Existence of Circulating Platelet Aggregates. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661600] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryBy a method of counting single platelets in diluted whole blood, platelet aggregates were quantified ex-vivo. Four groups: 20 thrombotic patients, 10 non-thrombotic patients, 10 healthy old controls and 10 healthy young controls were included in the study. Using a 19 gauge needle, with and without tubing, venous blood was taken into buffered EDTA, as a disaggregating agent and buffered EDTA-formalin, as the fixative. The amount of platelet aggregates quantified was affected by the quality of venepuncture or the rate of blood flow through the needle, but was unaffected by the presence of the tubing. There was no statistically significant difference between the four groups, in terms of the platelet aggregates quantified, but scanning electron microscopy revealed the presence of irreversible aggregates, composed of platelet red and white blood cells, in the blood of a greater number of thrombotic patients than non-thrombotic or healthy controls. Platelet aggregates were also quantified in aliquots of platelet rich plasma, and were found to be significantly greater than the corresponding values in whole blood. The difference appeared to be due to increased viscosity of the plasma, induced by the fixative which reduces platelet mobility during centrifugation. It is concluded that the platelet aggregates which disaggregate in bufffered EDTA may represent an artifact of blood collection; the irreversible aggregates are suspected to represent the in vivo circulating aggregates.
Collapse
Affiliation(s)
- A R Saniabadi
- The University Department of Medicine, Royal Infirmary, Glasgow, UK
| | - G D O Lowe
- The University Department of Medicine, Royal Infirmary, Glasgow, UK
| | - R Madhok
- The University Department of Medicine, Royal Infirmary, Glasgow, UK
| | - K Spowart
- The University Department of Medicine, Royal Infirmary, Glasgow, UK
| | - B Shaw
- The University Department of Medicine, Royal Infirmary, Glasgow, UK
| | - J C Barbenel
- The Bioengineering Unit, University of Strathclyde, Glasgow, UK
| | - C D Forbes
- The University Department of Medicine, Royal Infirmary, Glasgow, UK
| |
Collapse
|
12
|
Martínez García L, Pardo-Hernández H, Sanabria AJ, Alonso-Coello P, Penman K, McFarlane E, Martínez García L, Pardo-Hernández H, Sanabria A, Alonso-Coello P, Penman K, McFarlane E, Blanchard S, Brereton L, Browers M, Dean V, Flórez Gómez I, Fuentes C, Grimmer K, Harris J, Haynes C, Iorio A, James R, Kwong J, Lynch R, Nolan K, Ogunremi T, Okechukwu K, Prabhu Iyer N, Qaseem A, Rey M, Schorr S, Selva A, Shaw B, Shearn P, Shin E, Stapon C, Tam I, Thornton J, Uhl S, Vandvik P, Vernooij R. Guideline on terminology and definitions of updating clinical guidelines: The Updating Glossary. J Clin Epidemiol 2018; 95:28-33. [DOI: 10.1016/j.jclinepi.2017.11.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/08/2017] [Accepted: 11/28/2017] [Indexed: 11/30/2022]
|
13
|
Guey J, Rodrigues S, Pullen A, Shaw B, Kieser DC. Effect of ageing on the calibration of ballistic gelatin. J ROY ARMY MED CORPS 2018; 164:277-280. [PMID: 29487205 DOI: 10.1136/jramc-2018-000924] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 02/08/2018] [Accepted: 02/08/2018] [Indexed: 11/04/2022]
Abstract
PURPOSE Ballistic gelatin is commonly used as a validated surrogate for soft tissue during terminal ballistic testing. However, the effect of a delay between production and testing of a gelatin mould remains unknown. The aim of this study was to determine any potential effects of ageing on ballistic gelatin. METHODS Depth of penetration (DoP) of 4.5 mm spherical fragment simulating projectiles was ascertained using mixtures of 10%, 11.25% and 20% Type A 250 Bloom ballistic gelatin. Testing was performed daily for 5 days using velocities between 75 and 210 m/s. DoP at day 5 was statistically compared with day 1, and net mass change was recorded daily. RESULTS No significant difference was found for DoP observed with time in any of the samples (P>0.05). Spearman correlation was excellent in all moulds. The moulds with known standard calibrations remained in calibration throughout the study period. Mass loss of less than 1% was noted in all samples. CONCLUSION Mass loss was the only quantifiable measure of changes in the blocks with time, but did not correlate with any changes in DoP. This may provide reassurance when undertaking such testing that an inadvertent delay will not significantly alter the penetration properties of the mould. Future research is recommended to determine any potential effect on the mechanical properties of gelatin at higher velocity impacts and whether the calibration corresponds to an adequate simulation under such conditions.
Collapse
Affiliation(s)
- Jason Guey
- Defence Technology, Medical Corps, New Zealand Defence Force, Auckland, Auckland, New Zealand
| | - S Rodrigues
- Defence Technology, Medical Corps, New Zealand Defence Force, Auckland, Auckland, New Zealand
| | - A Pullen
- Defence Technology, Medical Corps, New Zealand Defence Force, Auckland, Auckland, New Zealand
| | - B Shaw
- Defence Technology, Medical Corps, New Zealand Defence Force, Auckland, Auckland, New Zealand
| | - D C Kieser
- Department of Orthopaedics, University of Otago, Dunedin, New Zealand
| |
Collapse
|
14
|
Thomas B, McIntosh D, Fildes T, Smith L, Hargrave F, Islam M, Thompson T, Layfield R, Scott D, Shaw B, Burrell CL, Gonzalez S, Taylor S. Second-harmonic generation imaging of collagen in ancient bone. Bone Rep 2017; 7:137-144. [PMID: 29124084 PMCID: PMC5671394 DOI: 10.1016/j.bonr.2017.10.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Revised: 09/27/2017] [Accepted: 10/24/2017] [Indexed: 12/01/2022] Open
Abstract
Second-harmonic generation imaging (SHG) captures triple helical collagen molecules near tissue surfaces. Biomedical research routinely utilizes various imaging software packages to quantify SHG signals for collagen content and distribution estimates in modern tissue samples including bone. For the first time using SHG, samples of modern, medieval, and ice age bones were imaged to test the applicability of SHG to ancient bone from a variety of ages, settings, and taxa. Four independent techniques including Raman spectroscopy, FTIR spectroscopy, radiocarbon dating protocols, and mass spectrometry-based protein sequencing, confirm the presence of protein, consistent with the hypothesis that SHG imaging detects ancient bone collagen. These results suggest that future studies have the potential to use SHG imaging to provide new insights into the composition of ancient bone, to characterize ancient bone disorders, to investigate collagen preservation within and between various taxa, and to monitor collagen decay regimes in different depositional environments. Second-Harmonic Generation (SHG) confocal laser scanning microscopy is used to investigate collagen remnants in ancient bone. Four independent techniques confirm the presence of collagen remnants in ancient bone samples with SHG-detected collagen. SHG imaging can visualise collagen remnants in ancient bone of various taxa, ages, and settings.
Collapse
Affiliation(s)
- B Thomas
- Mass Spectrometry Research Group, University of Liverpool, Brownlow Hill, Liverpool L69 3GJ, UK
| | - D McIntosh
- Mass Spectrometry Research Group, University of Liverpool, Brownlow Hill, Liverpool L69 3GJ, UK
| | - T Fildes
- Mass Spectrometry Research Group, University of Liverpool, Brownlow Hill, Liverpool L69 3GJ, UK.,Norton Priory Museum, Runcorn WA7 1SX, UK
| | - L Smith
- Norton Priory Museum, Runcorn WA7 1SX, UK
| | - F Hargrave
- Norton Priory Museum, Runcorn WA7 1SX, UK
| | - M Islam
- School of Science and Engineering, Teesside University, Borough Road, Middlesbrough TS1 3BA, UK
| | - T Thompson
- School of Science and Engineering, Teesside University, Borough Road, Middlesbrough TS1 3BA, UK
| | - R Layfield
- School of Life Sciences, University of Nottingham Medical School, Nottingham NG9 6HZ, UK
| | - D Scott
- School of Life Sciences, University of Nottingham Medical School, Nottingham NG9 6HZ, UK
| | - B Shaw
- School of Life Sciences, University of Nottingham Medical School, Nottingham NG9 6HZ, UK
| | - C L Burrell
- Liverpool John Moores University, Liverpool, UK
| | - S Gonzalez
- Liverpool John Moores University, Liverpool, UK
| | - S Taylor
- Mass Spectrometry Research Group, University of Liverpool, Brownlow Hill, Liverpool L69 3GJ, UK
| |
Collapse
|
15
|
Noble R, Dobrovin-Pennington A, Shaw B, Buss DS, Cross JV, Fountain MT. Fermentation for Disinfesting Fruit Waste From Drosophila Species (Diptera: Drosophilidae). Environ Entomol 2017; 46:939-945. [PMID: 28881957 DOI: 10.1093/ee/nvx107] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Indexed: 06/07/2023]
Abstract
Economic losses in a range of fruit crops due to the Drosophila suzukii (Matsumura) have become severe. Removal and treatment of fruit waste, which may harbor D. suzukii, is a key step in preventing reinfestation of fruit production. Natural fermentation for disinfesting fruit wastes from D. suzukii was examined at ambient air temperatures of 12-20 °C. Soft and stone fruit wastes infested with eggs, larvae, and pupae of Drosophila melanogaster (Meigen) or D. suzukii were placed in sealed vessels containing fruit wastes, and samples were retrieved at intervals and tested for the emergence of adults. Mean temperatures of the fruit waste in the sealed vessels during fermentation were 15-23 °C. Fermentation for 3 d was effective in disinfesting waste from different life stages of D. suzukii. Treatment for 4 d also ensured that the waste was free of viable life stages of D. melanogaster, which could be used as an indicator species for disinfestation of waste from D. suzukii owing to its greater tolerance of fermentation. The O2 concentration of the headspace air in the vessels became undetectable after 13-16 h, with a corresponding increase in CO2 concentration, which exceeded 80% vol/vol. The resulting hypoxia and hypercapnia may explain the efficacy of the fermentation treatment in disinfesting the waste. Fermented fruit remained attractive to D. suzukii and retained its capacity to rear a life cycle. Covering or mixing fermented fruit with a sufficient depth (0.1 m) or volume (×9) of soil or coir prevented the reinfestation of treated waste.
Collapse
Affiliation(s)
- R Noble
- NIAB EMR, East Malling, Kent, ME19?6BJ, United Kingdom
| | | | - B Shaw
- NIAB EMR, East Malling, Kent, ME19?6BJ, United Kingdom
| | - D S Buss
- NIAB EMR, East Malling, Kent, ME19?6BJ, United Kingdom
| | - J V Cross
- NIAB EMR, East Malling, Kent, ME19?6BJ, United Kingdom
| | - M T Fountain
- NIAB EMR, East Malling, Kent, ME19?6BJ, United Kingdom
| |
Collapse
|
16
|
Radivoyevitch T, Millard H, Shaw B, Brazauskas R, Savani B, Flowers M, Battiwalla M, Hamilton B, Sekeres M, Maciejewski J, Litzow M, Gale R, Dean R, Hashmi S. Autotransplants for Lymphoid Neoplasms Increase the Risks of MDS More Than AML. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30404-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Lovibond S, Shaw B. Mode of Presentation in STEMI Between Metropolitan and Rural Patients in South Eastern Victoria. Heart Lung Circ 2016. [DOI: 10.1016/j.hlc.2016.06.758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
18
|
Kargarfard M, Shariat A, Lam E, Shaw B, Shaw I, Shariat A, Nayyeri F. Prevalence and Perceptions Toward Anabolicandrogenic Steroid Use Amongst University Students. Acta Medica Bulgarica 2015. [DOI: 10.1515/amb-2015-0019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Summary
Anabolic-androgenic steroids (AASs) are highly sought-after in order to achieve muscle growth and better physical attributes. The study was conducted to measure the prevalence and attitudes towards the use of AASs among university students. 1008 male students from Isfahan University, Iran, between the ages of 18 and 25 years (23.3 ± 1.2 years) completed a questionnaire that investigated participation in bodybuilding, level of sport competition, participation in sports and recreational activities, AASs use, prevalence, knowledge among users, attitudes, as well as intent to continue using AASs in the future. 8% of respondents had used AASs and 6% currently use AASs. 71% of users believed using only a small amount of AASs or using AASs with anti-toxic drugs would not result in any harm, 10% indicated that AASs were harmless and 19% admitted to taking AASs despite knowing the adverse effects. 33% of respondents believed that they needed to use AASs to ensure athletic success and 26% believed that athletes should be allowed to use AASs without consequence. The prevalent use of AASs is a public health concern which implies that educational programmes at university level are needed to educate students about the adverse effects of AASs use
Collapse
Affiliation(s)
- M. Kargarfard
- Department of Sport Physiology, Faculty of Physical Education and Sport Sciences, University of Isfahan, Isfahan, Iran
| | - A. Shariat
- Department of Occupational Health, Faculty of Medicine and Health Sciences, University Putra, Malaysia
| | - E. Lam
- Department of Health and Human Performance, Cleveland State University, Cleveland, Ohio, USA
| | - B. Shaw
- Department of Sport and Movement Studies, University of Johannesburg, Republic of South Africa
| | - I. Shaw
- Department of Sport and Movement Studies, University of Johannesburg, Republic of South Africa
- Research Department, Monash University (South Africa Campus), Ruimsig, Republic of South Africa
| | - A. Shariat
- Department of Psychology, Faculty of Human Sciences, Islamic Azad University, Shahrekord, Isfahan, Iran
| | - Fereshteh Nayyeri
- Department of Computer, Science Faculty of Information Science and Technology University Kebangsaan Malaysia 43600 UKM Bangi, Selangor, Malaysia
| |
Collapse
|
19
|
Abstract
AbstractAlthough the elderly are thought to be at increased risk for acquiring nosocomial infections (NIs), the degree of risk has not been carefully quantified. We determined the decade-specific risks of NIs. The rate was constant at approximately 10 per 1,000 discharged patients from birth to 40 to 49 years. Thereafter the rate rose logarithmically and peaked at greater than 100 per 1,000 discharges after 70 years. Of all NIs, 64% occurred after 60 years of age. Yet, this elderly group made up only 23% of hospitalized patients. In conclusion, while the elderly comprise a small fraction of hospitalized patients, they account for the majority of nosocomial infections.
Collapse
|
20
|
Das-Gupta E, Dignan F, Shaw B, Raj K, Malladi R, Gennery A, Bonney D, Taylor P, Scarisbrick J. Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature. Bone Marrow Transplant 2014; 49:1251-8. [PMID: 24887389 DOI: 10.1038/bmt.2014.106] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2013] [Revised: 03/15/2014] [Accepted: 03/25/2014] [Indexed: 12/18/2022]
Abstract
Extracorporeal photopheresis (ECP) has been used for over 20 years to treat acute GVHD (aGVHD) and chronic GVHD. Evidence on the efficacy of response in aGVHD has continued to accrue and data suggest that there is a good response and prolonged survival in both children and adults with grade II-IV aGVHD. Unlike chronic GVHD where treatment schedules are typically one or two times monthly for 12-18 months, patients with aGVHD respond rapidly to an intense weekly treatment schedule for 8 weeks, typically allowing steroids to be discontinued without flare-ups of aGVHD. Maintenance ECP therapy is generally not required. Many centres across Europe and United States treat aGVHD with ECP as second-line therapy and responses are excellent in a subset of patients. Unlike other second-line therapies, ECP is not immunosuppressive and has no reported drug interactions. Importantly, ECP does not have a negative impact on the graft-versus-malignancy effect of the transplant. This statement aims to select those patients most likely to respond to treatment and summarises treatment and monitoring schedules for the management of aGVHD in adult and paediatric patients to ensure the correct patients are treated with the optimal protocol for efficacy.
Collapse
Affiliation(s)
- E Das-Gupta
- Centre for Clinical Haematology, Nottingham University Hospitals NSH Trust, Nottingham, UK
| | - F Dignan
- Central Manchester University Hospitals, Manchester, UK
| | - B Shaw
- Royal Marsden Hospital, London, UK
| | - K Raj
- King's College Hospital, London, UK
| | - R Malladi
- University Hospital Birmingham NHS Trust, Birmingham, UK
| | - A Gennery
- Great North Children's Hospital, Newcastle-Upon-Tyne, UK
| | - D Bonney
- Royal Manchester Children's Hospital, Manchester, UK
| | - P Taylor
- Rotherham Foundation NHS Trust, Rotherham, South Yorkshire, UK
| | - J Scarisbrick
- University Hospital Birmingham NHS Trust, Birmingham, UK
| |
Collapse
|
21
|
Banerjee S, Manley K, Thomas L, Shaw B, Saxton J, Mills R, Rochester M. O2 Preoperative exercise protocol to aid recovery of radical cystectomy: Results of a feasibility study. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/s1569-9056(13)62320-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
22
|
Zou LE, Kabakova IV, Mägi EC, Li E, Florea C, Aggarwal ID, Shaw B, Sanghera JS, Eggleton BJ. Efficient inscription of Bragg gratings in As2S3 fibers using near bandgap light. Opt Lett 2013; 38:3850-3853. [PMID: 24081069 DOI: 10.1364/ol.38.003850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Efficient inscription of Fiber Bragg gratings (FBGs) in single-mode, thin cladding As(2)S(3) fibers is demonstrated by using near bandgap light at 532 nm. The FBGs with the reflectivity of over 80% can be induced in only 80-90 s, substantially faster than in previous reports. The dynamics of the grating growth are investigated in the photosensitivity process, showing a fast blue shift of the Bragg wavelength and then a somewhat slower red shift. The aging of the grating after fabrication is also reported, indicating a 37% decay of the grating strength.
Collapse
|
23
|
Petersdorf EW, Malkki M, Hsu K, Bardy P, Cesbron A, Dickinson A, Dubois V, Fleischhauer K, Kawase T, Madrigal A, Morishima Y, Shaw B, Spellman S, Spierings E, Stern M, Tiercy JM, Velardi A, Gooley T. 16th IHIW: international histocompatibility working group in hematopoietic cell transplantation. Int J Immunogenet 2012; 40:2-10. [PMID: 23279968 DOI: 10.1111/iji.12022] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2012] [Revised: 10/22/2012] [Accepted: 10/23/2012] [Indexed: 11/28/2022]
Abstract
The International Histocompatibility Working Group is a collaborative international effort to understand the HLA and non-HLA genetics of the transplantation barrier. The Working Group is comprised of experts in the fields of histocompatibility and immunogenetics, hematopoietic cell transplantation and outcomes research. Data for 25 855 unrelated donor transplants were submitted in support of research studies for the 16th International Histocompatibility Workshop. Active investigation is in progress in seven key areas: the impact of HLA matching, role of race and ethnicity, identification of permissible HLA mismatches, haplotype-associated determinants, minor histocompatibility antigens, immune response genes and KIR genetics. New hypotheses for the 16th workshop were developed for immunogenetic studies in cord blood and haploidentical-related donor transplantation.
Collapse
Affiliation(s)
- E W Petersdorf
- Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Sackeyfio A, Senthinathan A, Kandaswamy P, Barry PW, Shaw B, Baker M. Diagnosis and assessment of food allergy in children and young people: summary of NICE guidance. BMJ 2011; 342:d747. [PMID: 21345912 DOI: 10.1136/bmj.d747] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- A Sackeyfio
- Centre for Clinical Practice, National Institute for Health and Clinical Excellence, Manchester M1 4BD, UK
| | | | | | | | | | | |
Collapse
|
25
|
Crane JK, Tietbohl G, Arnold P, Bliss ES, Boley C, Britten G, Brunton G, Clark W, Dawson JW, Fochs S, Hackel R, Haefner C, Halpin J, Heebner J, Henesian M, Hermann M, Hernandez J, Kanz V, McHale B, McLeod JB, Nguyen H, Phan H, Rushford M, Shaw B, Shverdin M, Sigurdsson R, Speck R, Stolz C, Trummer D, Wolfe J, Wong JN, Siders GC, Barty CPJ. Progress on converting a NIF quad to eight, petawatt beams for advanced radiography. ACTA ACUST UNITED AC 2010. [DOI: 10.1088/1742-6596/244/3/032003] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
26
|
King RJ, Confer DL, Greinix HT, Halter J, Horowitz M, Schmidt AH, Costeas P, Shaw B, Egeland T. Unrelated hematopoietic stem cell donors as research subjects. Bone Marrow Transplant 2010; 46:10-3. [PMID: 20190845 DOI: 10.1038/bmt.2010.37] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Requests for participation of unrelated stem cell donors in research transplant protocols are becoming more frequent. World Marrow Donor Association calls on donor registries to participate in research activities. Here, we discuss various implications of research participation and make some recommendations as how to make this possible.
Collapse
Affiliation(s)
- R J King
- National Marrow Donor Program, Minneapolis, MN, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Shaw B. Improving services for cleft lip and palate. A work in progress. Community Dent Health 2010; 27:2-3. [PMID: 20426253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Cleft lip and palate remains an orphan condition, falling between a variety of clinical disciplines, and often forgotten by public health consultants and health commissioners. Much remains to be done, and in the absence of leadership from clinicians or commissioners, progress may have to await the emergence of a stronger voice from organizations representing affected families.
Collapse
|
28
|
Abstract
The effects of sodium salicylate and of aspirin on the actions of pancreatic, salivary and serum kallikreins have been investigated. Kinin production by the three enzymes was assessed using a guinea-pig isolated ileum preparation. The esterolytic activity of pancreatic and salivary kallikreins was measured by determining acid release from the synthetic substrate toluene-p-sulphonyl-L-arginine methyl ester. Sodium salicylate (up to 20 mM) or aspirin (up to 5 mM) failed to inhibit kinin production by each of the three enzymes. With salivary kallikrein, a concentration of 50 mM of sodium salicylate was required to produce a 50% inhibition of kinin production. No significant inhibition of esterolytic activity was produced by concentrations up to 5 mM of either sodium salicylate or aspirin. Prior incubation of sodium salcylate or aspirin with the enzymes also resulted in no significant effect of either drug on kinin production or esterolytic activity. Prior incubation of pancreatic or salivary kallikrein with the inhibitor from ox parotid gland (Trasylol) reduced both kinin production and esterolytic activity. Toluene-p-sulphonyl-L-arginine methyl ester (0.5 mM) inhibited kinin production by each of the three enzymes. It is concluded that sodium salicylate and aspirin are poor inhibitors of kallikrein activity in vitro.
Collapse
|
29
|
Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2008. [DOI: 10.1111/j.1365-2141.2000.02475.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Shaw B, Cheater F, Baker R, Gillies C, Hearnshaw H, Flottorp S, Robertson N. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2005:CD005470. [PMID: 16034980 DOI: 10.1002/14651858.cd005470] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND Strategies to implement change in health professional performance have variable impact. A potential explanation is that the barriers to implementation are different in different settings and at different times. Change may be more likely if the strategies were specifically chosen to address the identified barriers. OBJECTIVES To assess the effectiveness of strategies tailored to address specific, identified barriers to change in professional performance. SEARCH STRATEGY We searched the Cochrane Effective Practice and Organisation of Care Group (EPOC) specialised register and pending files until end of December 2002. English language articles only were included. SELECTION CRITERIA Randomised controlled trials (RCTs) that reported objectively measured professional practice or health care outcomes in which at least one group received an intervention designed (or tailored) to address prospectively identified barriers to change. DATA COLLECTION AND ANALYSIS Two reviewers independently extracted data and assessed quality. We also contacted study authors to obtain any missing information. Quantitative and qualitative analyses were undertaken. MAIN RESULTS We included 15 studies. For Comparison 1 (an intervention tailored to address identified barriers to change compared to no intervention or an intervention(s) not tailored to the barriers), there was no consistency in the results and the effect sizes varied both across and within studies.A meta-regression of a subset of the included studies, using a classical approach estimated a combined OR of 2.18 (95% CI: 1.09, 4.34), p = 0.026 in favour of tailored interventions. However, when a Bayesian approach was taken, meta-regression gave a combined OR of 2.27 (95% Credible Interval: 0.92, 4.75), which was not statistically significant. AUTHORS' CONCLUSIONS Interventions tailored to prospectively identify barriers may improve care and patient outcomes. However, from the studies included in this review, we were unable to determine whether the barriers were valid, which were the most important barriers, whether all barriers were identified and if they had been addressed by the intervention chosen. Based on the evidence presented in this review, the effectiveness of tailored interventions remains uncertain and more rigorous trials (including process evaluations) are needed. Further research needs to address explicitly the questions of identifying and addressing barriers.
Collapse
Affiliation(s)
- B Shaw
- Clinical Governance Research & Development Unit, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester, Leicestershire, UK, LE5 4PW.
| | | | | | | | | | | | | |
Collapse
|
31
|
Rittig MG, Shaw B, Letley DP, Thomas RJ, Argent RH, Atherton JC. Helicobacter pylori-induced homotypic phagosome fusion in human monocytes is independent of the bacterial vacA and cag status. Cell Microbiol 2004; 5:887-99. [PMID: 14641174 DOI: 10.1046/j.1462-5822.2003.00328.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Following reports that a VacA+cag+ toxigenic but not a VacA-cag- non-toxigenic Helicobacter pylori strain induced homotypic phagosome fusion in murine macrophages, we addressed that phenomenon in human cells. Mononuclear phagocytes and epitheloid cells were challenged with H. pylori strains of different vacA and cag genotypes and with VacA- and Cag- isogenic mutants, and chased in the absence or presence of signal transduction modulators. Electron microscopy revealed that, in monocytes: (i) homotypic phagosome fusion was frequently induced by all live H. pylori strains investigated but not by exogenous VacA; (ii) phagosomes containing bacteria fused, but not those containing latex beads; (iii) fusion resulted in communal compartments resembling giant multivesicular bodies; and (iv) formation of these compartments was blocked by inhibiting the host cell regulators PI 3-kinase, phospholipase C and p42 MAP kinase. Whereas some internalized bacteria remained viable 1 h after uptake, none survived a 24 h period. In contrast to monocytes, infected epitheloid cells rarely developed communal compartments. In combination, these results demonstrate that, in human monocytes, the H. pylori-induced homotypic phagosome fusion depends on neither the vacuolating cytotoxin VacA nor the cag pathogenicity island of H. pylori and does not result in prolonged intracellular survival.
Collapse
Affiliation(s)
- M G Rittig
- Centre for Biochemistry and Cell Biology, Institute of Infections, Immunity and Inflammation, University of Nottingham Meeical School, UK.
| | | | | | | | | | | |
Collapse
|
32
|
Washington B, Mtshali C, Williams S, Smith H, Li JD, Shaw B, Gwathmey J. Ethanol-induced mitogen activated protein kinase activity mediated through protein kinase C. Cell Mol Biol (Noisy-le-grand) 2003; 49:1351-6. [PMID: 14984009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The aim of this study was to determine the pathway(s) by which ethanol activates mitogen-activated protein kinase (MAPK) signaling and to determine the role of Ca2+ in the signaling process. MAPK signaling was determined by assessing MAPK activity, measuring phosphorylated extracellular signaling-regulated kinase (pp 44 ERK-1 and pp 42 ERK-2) expression and ERK activity by measuring ERK-2-dependent phosphorylation of a synthetic peptide as a MAPK substrate in rat vascular smooth muscle cells. Ethanol activated extracellular signal-regulated kinase expression (ERK 1 and 2) could be observed when vascular smooth muscle cells (VSMCs) were stimulated for 5 min or less, but was inhibited when cells are treated for 10 min or more with 1-16 mM of ethanol. Maximum ethanol-induced MAPK activity was observed within 5 min with 4 or 8 mM. Ethanol stimulated MAPK activity was blocked by the protein kinase C (PKC) inhibitor (GF109203X) and epidermal growth factor (EGF) receptor antagonist (PD153035) by 41 +/- 24 and 34 +/- 12.3%, respectively. The calcium channel blocker, diltiazem and the chelating agent, BAPTA, reduced the activation of MAPK activity by ethanol, significantly. The data demonstrate that ethanol-stimulated MAPK expression is mediated partially through both the EGF-receptor and PKC intermediates and that activation through the PKC intermediate is calcium-dependent.
Collapse
Affiliation(s)
- B Washington
- Biomedical Research Center, Tennessee State University, Nashville, TN 37209, USA.
| | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
A 46-year-old-man received high dose chemotherapy and an autologous stem-cell transplant for multiple plasmacytoma. He had a prolonged period of pancytopenia post-transplantation, which was thought to be due to a suboptimal dose of transplanted stem cells in combination with the effects of interferon therapy and an altered bone marrow microenvironment. Twenty-eight months after the transplant he was found to be hyperthyroid. Anti-thyroid therapy has led to a sustained improvement in his pancytopenia.
Collapse
Affiliation(s)
- B Shaw
- Department of Haematology, Royal Free Hospital, London, UK
| | | |
Collapse
|
34
|
Sudan DL, Chinnakotla S, Horslen S, Iyer K, Fox I, Shaw B, Langnas AN. Basiliximab decreases the incidence of acute rejection after intestinal transplantation. Transplant Proc 2002; 34:940-1. [PMID: 12034250 DOI: 10.1016/s0041-1345(02)02681-7] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- D L Sudan
- University of Nebraska Medical Center, Nebraska Health Systems, Omaha, Nebraska 68198, USA
| | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
Biocomposite films comprising a non-crosslinked, natural polymer (collagen) and a synthetic polymer, poly(epsilon-caprolactone) (PCL), have been produced by impregnation of lyophilised collagen mats with a solution of PCL in dichloromethane followed by solvent evaporation. This approach avoids the toxicity problems associated with chemical crosslinking. Distinct changes in film morphology, from continuous surface coating to open porous format, were achieved by variation of processing parameters such as collagen:PCL ratio and the weight of the starting lyophilised collagen mat. Collagenase digestion indicated that the collagen content of 1:4 and 1:8 collagen:PCL biocomposites was almost totally accessible for enzymatic digestion indicating a high degree of collagen exposure for interaction with other ECM proteins or cells contacting the biomaterial surface. Much reduced collagen exposure (around 50%) was measured for the 1:20 collagen:PCL materials. These findings were consistent with the SEM examination of collagen:PCL biocomposites which revealed a highly porous morphology for the 1:4 and 1:8 blends but virtually complete coverage of the collagen component by PCL in the 1:20 samples. Investigations of the attachment and spreading characteristics of human osteoblast (HOB) cells on PCL films and collagen:PCL materials respectively, indicated that HOB cells poorly recognised PCL but attachment and spreading were much improved on the biocomposites. The non-chemically crosslinked, collagen:PCL biocomposites described are expected to provide a useful addition to the range of biomaterials and matrix systems for tissue engineering.
Collapse
Affiliation(s)
- A G A Coombes
- School of Biomedical Sciences, University of Nottingham, Queen's Medical Centre, UK.
| | | | | | | | | | | |
Collapse
|
36
|
Sudan D, Iyer K, Horslen S, Shaw B, Langnas A. Assessment of quality of life after pediatric intestinal transplantation by parents and pediatric recipients using the child health questionnaire. Transplant Proc 2002; 34:963-4. [PMID: 12034262 DOI: 10.1016/s0041-1345(02)02718-5] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- D Sudan
- University of Nebraska Medical Center, Omaha, Nebraska 68198, USA
| | | | | | | | | |
Collapse
|
37
|
Sudan D, Grant W, Iyer K, Shaw B, Horslen S, Langnas A. Oral beclomethasone therapy for recurrent small bowel allograft rejection and intestinal graft-versus-host disease. Transplant Proc 2002; 34:938-9. [PMID: 12034249 DOI: 10.1016/s0041-1345(02)02680-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- D Sudan
- University of Nebraska Medical Center, Omaha, Nebraska, USA
| | | | | | | | | | | |
Collapse
|
38
|
Horslen S, Torres C, Collier D, Iyer K, Sudan D, Shaw B, Langas A. Initial experience using rapamycin immunosuppression in pediatric intestinal transplant recipients. Transplant Proc 2002; 34:934-5. [PMID: 12034246 DOI: 10.1016/s0041-1345(02)02677-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- S Horslen
- Pediatric GI, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA
| | | | | | | | | | | | | |
Collapse
|
39
|
Langnas A, Chinnakotla S, Sudan D, Horslen S, McCashland T, Schafer D, Sorrell M, Vanderhoof J, Iyer K, Fox I, Shaw B. Intestinal transplantation at the University of Nebraska Medical Center: 1990 to 2001. Transplant Proc 2002; 34:958-60. [PMID: 12034260 DOI: 10.1016/s0041-1345(02)02716-1] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- A Langnas
- University of Nebraska Medical Center, Omaha, Nebraska 68198, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
We examined the use of stream baseflow water quality as a representative measure of mean ground water quality in the Tomorrow-Waupaca Watershed in central Wisconsin and the relationship between agricultural land use and watershed water quality. From 1997 to 1999, 38 stream sites were sampled for nitrate during winter and summer baseflow conditions. Some sites have been sampled during winter baseflow conditions since 1994. The land area contributing ground water to each stream sampling site was delineated, resulting in 38 sub-basins. In addition, over 3500 test results from private wells in the watershed were compiled and mapped using a Geographic Information System (GIS). Nitrate concentrations in stream baseflow and well waters were found to have strong positive correlation in the sub-basins of second order or higher. This indicates that stream baseflow may be valid for monitoring mean ground water quality in watersheds predominantly fed by ground water, where much of the stream nitrate is believed to originate from ground water. Analysis of seasonal variation in the stream data showed that winter nitrate concentrations were higher than summer concentrations, implying that winter stream monitoring may be more critical for the assessment of overall ground water quality in the watershed. We also found that, as the amount of agricultural land increased in each sub-basin, average nitrate concentrations in the well and stream waters also increased, suggesting a connection between agricultural land use and nitrate contamination of water resources in the watershed.
Collapse
Affiliation(s)
- H Lin
- Department of Crop and Soil Sciences, Pennsylvania State University, University Park 16802, USA.
| | | | | |
Collapse
|
41
|
Hauke R, Smir B, Greiner T, Bierman P, Tarantolo S, Anderson J, Shaw B, Armitage J. Clinical and pathological features of posttransplant lymphoproliferative disorders: influence on survival and response to treatment. Ann Oncol 2001; 12:831-4. [PMID: 11484960 DOI: 10.1023/a:1011131700811] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE To review the clinical and pathological characteristics of patients with posttransplant lymphoproliferative disorders (PTLD) occurring after solid organ transplantation and determine the influence of these characteristics on response to treatment and survival. PATIENTS AND METHODS Retrospective review of 32 patients. RESULTS Overall five-year survival was 59%. Forty-five percent of patients diagnosed within the first year after transplant had advanced disease. Characteristics that were associated with poorer survival were diagnosis within the first year posttransplant, monoclonal tumors and presentation with an infectious mononucleosis-like syndrome. Six of eight patients treated with surgery are alive and disease-free. CONCLUSION Patients with PTLD can achieve long-term survival. Surgery can play an important role in selected patients. Characteristics that may be associated with poorer survival are diagnosis within the first year after transplant, presence of a monoclonal tumor or an infectious mononucleosis-like presentation.
Collapse
Affiliation(s)
- R Hauke
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-7680, USA.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
PURPOSE The aim of this study was to determine long-term results of intestinal transplantation in children with pseudo-obstruction, particularly when stomach and colon are not part of the allograft. METHODS The authors conducted a case-record review of all children who underwent transplantation at our center for a primary diagnosis of pseudo-obstruction. Supplementary information was obtained from outpatient charts, computerized database, and telephone survey of parents. RESULTS Six small bowel and 3 liver-small bowel transplants were carried out in 8 patients between 1993 and 1999. Median follow-up is 40 months (range, 13 to 73 months). Median age at transplantation was 2.7 years (range, 0.7 to 12.8 years). Median graft survival in this series is 15 months (range, 1 day to 71 months). Stomach and colon were excluded from all allografts. Two children died 5 and 368 days after transplant and 2 graft losses occurred in 1 patient. Two children had lymphoproliferative disease; both are alive with functioning grafts. Five survivors with functioning grafts receive full enteral feedings at home. Four of the 5 have had ileostomies closed, and 3 have normal bowel movements. CONCLUSIONS Intestinal transplantation without stomach or colon provides children with chronic intestinal pseudo-obstruction with a good quality of life. The underlying disease poses special challenges in management.
Collapse
Affiliation(s)
- K Iyer
- Organ Transplantation Program, University of Nebraska Medical Center, Omaha, NE 68198-3285, USA
| | | | | | | | | | | | | |
Collapse
|
43
|
Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111:1122-9. [PMID: 11167751 DOI: 10.1046/j.1365-2141.2000.02475.x] [Citation(s) in RCA: 144] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Severe hepatic veno-occlusive disease (VOD) is a recognized complication of autologous and allogeneic stem cell transplantation (SCT) that is often fatal. Defibrotide (DF) is a polydeoxyribonucleotide that has been found to have anti-thrombotic, anti-ischaemic and thrombolytic properties without causing significant anticoagulation. Preliminary studies have demonstrated activity for DF in the treatment of VOD, with minimal associated toxicity. In the present study, 40 patients who fulfilled established criteria for VOD were treated with DF on compassionate grounds in 19 European centres; 28 patients met risk criteria predicting progression of VOD and fatality or had evidence of multiorgan failure (MOF), and were defined as 'poor-risk'. DF was commenced intravenously at a median of 14 d (range, -2 d to 53 d) post SCT at doses ranging from 10 to 40 mg/kg. The median duration of therapy was 18 d (range, 2--71 d). Twenty-two patients showed a complete response (CR) (bilirubin < 34.2 micromol/l and resolution of signs/symptoms of VOD and end-organ dysfunction) [CR = 55%, confidence interval (CI) 40--70%] and 17 patients (43%) are alive beyond d +100. Ten poor-risk patients showed a complete response (CR = 36%, CI 21--51%). These results demonstrate that DF is an active treatment for VOD following SCT and a randomized trial is now underway in order to further evaluate its role.
Collapse
Affiliation(s)
- R Chopra
- Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
McClane S, Renner G, Bell PL, Early EK, Shaw B. Pilot study to evaluate the efficacy of hyperbaric oxygen therapy in improving the survival of reattached auricular composite grafts in the New Zealand White rabbit. Otolaryngol Head Neck Surg 2000; 123:539-42. [PMID: 11077336 DOI: 10.1067/mhn.2000.109473] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE This investigation is a prospective, randomized, blinded study seeking to evaluate the efficacy of hyperbaric oxygen (HBO) therapy in improving the survival of the reattached auricular composite graft. STUDY DESIGN Twenty New Zealand White rabbits were randomly assigned to control (10) and treatment (10) groups in a prospective fashion. After amputation and reattachment of measured segments of each ear, the treatment group received 14 HBO treatments for 10 days. The control group received only standard postoperative care. On postoperative day 18, the surviving composite grafts were measured, recorded, and statistically analyzed. RESULTS The mean percentage of graft survival for the control group was 0.31% (range 0%-2.5%), and the mean for the group receiving HBO was 15.94% (range 0%-38%). A median test was used to evaluate this difference, which was found to be statistically significant (P = 0057). CONCLUSION Our study appears to indicate a possible survival benefit for the composite grafts in those rabbits that received HBO treatments. We believe that there are several significant difficulties with the rabbit as a model for this study, but we are encouraged at this point that a limited measurable benefit was observed. Further investigations with HBO appear to be warranted at this time.
Collapse
Affiliation(s)
- S McClane
- Division of Otolaryngology-Head and Neck Surgery, University of Missouri Hospitals and Clinics, Columbia, USA
| | | | | | | | | |
Collapse
|
45
|
Abstract
The Aquatic Macrophyte Community Index (AMCI) is a multipurpose tool developed to assess the biological quality of aquatic plant communities in lakes. It can be used to specifically analyze aquatic plant communities or as part of a multimetric system to assess overall lake quality for regulatory, planning, management, educational, or research purposes. The components of the index are maximum depth of plant growth; percentage of the littoral zone vegetated; Simpson's diversity index; the relative frequencies of submersed, sensitive, and exotic species; and taxa number. Each parameter was scaled based on data distributions from a statewide database, and scaled values were totaled for the AMCI value. AMCI values were grouped and tested by ecoregion and lake type (natural lakes and impoundments) to define quality on a regional basis. This analysis suggested that aquatic plant communities are divided into four groups: (1) Northern Lakes and Forests lakes and impoundments, (2) North-Central Hardwood Forests lakes and impoundments, (3) Southeastern Wisconsin Till Plains lakes, and (4) Southeastern Wisconsin Till Plains impoundments, Driftless Area Lakes, and Mississippi River Backwater lakes. AMCI values decline from group 1 to group 4 and reflect general water quality and human use trends in Wisconsin. The upper quartile of AMCI values in any region are the highest quality or benchmark plant communities. The interquartile range consists of normally impacted communities for the region and the lower quartile contains severely impacted or degraded plant communities. When AMCI values were applied to case studies, the values reflected known impacts to the lakes. However, quality criteria cannot be used uncritically, especially in lakes that initially have low nutrient levels.
Collapse
Affiliation(s)
- S Nichols
- Wisconsin Geological and Natural History Survey, 3817 Mineral Point Rd., Madison, Wisconsin 53705, USA, USA
| | | | | |
Collapse
|
46
|
Paterson PJ, Marshall SR, Shaw B, Kendra JR, Ethel M, Kibbler CC, Prentice HG, Potter M. Fatal invasive cerebral Absidia corymbifera infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26:701-3. [PMID: 11041574 DOI: 10.1038/sj.bmt.1702575] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
A 56-year-old dairy farmer received a fully HLA matched unrelated donor marrow transplant for high risk CML in chronic phase. His early post-transplant course was complicated by a series of massive intracerebral bleeds and by sepsis related to a malignant otitis externa. The microbial pathogen isolated from ear swabs was found to be Absidia corymbifera, but CT scan at the time showed no intracerebral extension. Despite neutrophil engraftment and aggressive antifungal management he succumbed. Autopsy revealed invasion of Absidia into the brain from the ear. We speculate that colonisation by Absidia resulted from occupational exposure.
Collapse
Affiliation(s)
- P J Paterson
- Department of Haematology, Royal Free Hospital, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
BACKGROUND Bronchopulmonary dysplasia (BPD) is a chronic disorder associated with prematurity. Systemic steroids induce at least a temporary improvement in respiratory function, but are associated with adverse side effects. Inhaled steroids have fewer side effects. OBJECTIVES To determine if inhaled corticosteroids are effective in alleviating the morbidity of bronchopulmonary dysplasia (BPD) compared to 0-placebo. SEARCH STRATEGY We identified randomised, controlled trials (RCT) within the Cochrane Database, references from retrieved trials, hand searches of journals and contact with pharmaceutical companies and experts in this field. SELECTION CRITERIA Only randomised controlled trials involving infants with chronic lung disease of prematurity and treated with inhaled steroids versus placebo were included. Patients receiving systemic corticosteroids were excluded. Co-interventions included antenatal systemic steroids, routine neonatal intensive care, ventilatory support, surfactant replacement therapy, diuretics and bronchodilators. DATA COLLECTION AND ANALYSIS Four of the seven included trials were of good methodological quality. There were five parallel-group trials in ventilated infants. These were comparable in terms of population, co-interventions and need for increased inspired oxygen concentration. They differed in terms of type, dose and duration (7-28 days) of inhaled steroids. Two cross-over trials were performed in non-ventilated patients. MAIN RESULTS The inability to extubate during treatment was markedly reduced in infants treated with inhaled steroids; Peto Odds Ratio (OR) 0.12, 95% Confidence Interval (CI) 0.03 to 0.43. There was heterogeneity in this finding, however, with one study that contributed 30% of the total number of patients reporting no successful extubations in either treatment arm over one week. The risk of sepsis appeared similar between the two groups (N=3, OR=0.72, 95%CI: 0.21 to 2.43). The small number of trials precluded analysis to examine the effect of differences in drug, duration of therapy, delivery system, co-interventions, and disease severity. Reduced oxygen requirements were reported in one of the two trials performed in non-ventilated infants, but inadequate data reporting precluded pooling of data. REVIEWER'S CONCLUSIONS In ventilated infants with BPD, inhaled steroids administered for 1 to 4 weeks improved the rate of extubation with no apparent increase in the risk of sepsis. No firm conclusion could be derived with regard to the efficacy of inhaled steroids in non-ventilated infants.
Collapse
Affiliation(s)
- P Lister
- PICU, Addenbrookes Hospital, Hills Road, Cambridge, UK.
| | | | | | | |
Collapse
|
48
|
Brown I, Shaw B. Routine child health care in the emergency department. Can J Public Health 1999; 90:424-5. [PMID: 10680271 PMCID: PMC6980104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Affiliation(s)
- I Brown
- Centre for Health Promotion, University of Toronto, ON.
| | | |
Collapse
|
49
|
Abstract
The use of porous spherical orbital implants enables ocular prosthesis motility to be improved if necessary by subsequent drilling of the implant and coupling it to the prosthesis with a peg. We compared the effect of drilling at different speeds on hydroxyapatite and porous polyethylene (Medpor) spherical implants. The implants were drilled at fixed speeds of between 15 and 2000 revolutions per minute. The samples were then viewed in an electron microscope and photographed. When hydroxyapatite is drilled the porous structure of the implant is maintained although a precise hole with well-defined walls was not produced. This contrasts with porous polyethylene where the porous structure is lost although a precise drill hole is created. This drilling technique has been used successfully in patients with hydroxyapatite implants, thus making possible stable epithelialisation of the drill hole. Our results confirm that the drilling of porous polyethylene using this technique is unlikely to be successful, as loss of the porous structure would prevent stable epithelialisation of the drill hole, resulting in exposure of the implant.
Collapse
Affiliation(s)
- R B. Dapling
- Department of Ophthalmology, Royal Shrewsbury Hospital, NHS Trust, Shrewsbury, U.K
| | | | | | | | | | | |
Collapse
|
50
|
Nieuwenhuyzen M, Keirse R, Shaw B, Vos JG. A 2:1 co-crystal of 5-(2-pyridyl)-1H-1,2,4-triazole and 1,4-dihydroxybenzene. Acta Crystallogr C 1999. [DOI: 10.1107/s0108270198012359] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|